GlassScriptPhysician profile
David Reis
NPI 1144046905
$3,241.62
in general payments reported to CMS, 2019-2025
40 companies · $3,242 in 2025
The $3,242 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.63 |
| Education | $277.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $484.62 | 2025 | Erleada, Talvey, Balversa |
| Daiichi Sankyo INC. | $327.48 | 2025 | Enhertu, Datroway |
| Genentech USA, INC. | $204.06 | 2025 | Polivy, Tecentriq, Phesgo |
| Pfizer INC. | $160.09 | 2025 | |
| Merck Sharp & Dohme LLC | $144.68 | 2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $139.69 | 2025 | Enhertu, Lynparza |
| Incyte Corporation | $133.06 | 2025 | Jakafi, Niktimvo, Zynyz |
| Astellas Pharma US INC | $126.92 | 2025 | Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $116.46 | 2025 | Iclusig, Ninlaro |
| Eisai INC. | $115.66 | 2025 | |
| Novartis Pharmaceuticals Corporation | $104.95 | 2025 | |
| Seagen INC. | $99.00 | 2025 | |
| Celgene Corporation | $94.00 | 2025 | Reblozyl |
| Emd Serono, INC. | $89.10 | 2025 | |
| Beone Medicines USA, INC. | $78.98 | 2025 | Brukinsa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.